Please login to the form below

White paper for download: The vicious circle of pharmaceutical tendering

In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.

With the tendering process becoming increasingly important in pharmaceutical procurement, accounting for around 25% of total global pharmaceutical turnover, it’s important to understand the impacts and risks that could affect you. In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.

Download the white paper now for insight into:

  • What tendering entails
  • The importance of tendering for pharma
  • The effect of epoetin tendering
  • How the ‘winner takes all’ pricing game works
  • The risks that create a vicious circle of tendering

Download the white paper here: https://www.validinsight.com/resource-center/the-vicious-circle-of-pharmaceutical-tendering/

25th September 2019

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

RWE Blog 2: Payers use real-world data cautiously
Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
RWE Blog 1: Real-world challenges and real-world data
This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight
Valid News, Market Access Insights, Issue 3
Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.
Valid Insight
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published the 21st edition of the EML, recommending the inclusion of 28 new medicines.
Valid Insight
Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019
For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress
Valid Insight
Confidential contracting – the road to flexible pricing
Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.
Valid Insight